CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

Summary

This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.

Timeline

Start

2024-06-27

Primary completion

2028-06

Completion

2029-06

Drugs

Indications